In a recent study, researchers evaluated the treatment effect size of amphetamine extended-release oral suspension (AMPH EROS) throughout the day in children aged 6 to 12 years old with attention-deficit/hyperactivity disorder (ADHD).
The study’s lead author, Stephen V Faraone, reported that AMPH EROS had effective effect sizes throughout the day, including early in the morning, in the treatment of ADHD. The data were published in the Journal of Child and Adolescent Psychopharmacology.
These results were based on post hoc analyses of a 5-week, dose-adjusted, double-blinded randomized controlled trial that evaluated the safety and efficacy of AMPH EROS in 99 children with ADHD within a laboratory classroom setting. Researchers assessed overall effect size and size at 1, 2, 4, 6, 8, 10, 12, and 13 hours after dosing.
Amphetamine Extended-Release Oral Suspension Efficacy Over Time
The primary analysis was change from baseline Swanson, Kotkin, Agler, M-Flynn, Pelham (SKAMP)-C, and secondary analyses included change in SKAMP attention and deportment subscales, as well as Permanent Product Measure of Performance (PERMP) problems attempted and problems correct. Investigators used linear mixed model repeated-measure models to assess AMPH EROS efficacy.
Authors stated that AMPH EROS demonstrated large (Cohen’s d=0.8) overall effect sizes across the primary and secondary efficacy assessments. Furthermore, SKAMP-C, PERMP problems attempted, and PERMP problems correct had large effect sizes at each time point, while SKAMP-A and SKAMP-D scores ranged from a medium (Cohen’s d=0.5) to large treatment effect size at each time point.
Ultimately, the authors summarized that “AMPH EROS demonstrated robust and consistent effects beginning early in the morning and continuing throughout the day in the treatment of symptoms of ADHD in children aged 6–12 years.”